Rorer Pharmaceutical Corporation

Raymond Youssefyeh

Henry F Campbell

Donald E Kuhla

Scott I Klein

Rohit M Desai

Ernest Magnien

Utpal Chakraborty

Thomas D Lee

Certain specific substituted 9-N-(1-azabicycolo-[2.2.2.]octan-3-yl)carboxamido-2,3,4,5-tetrahydro-1-ben zoxepins and their valuable use as 5-HT.sub.3 antagonists having CNS and gastric prokinetic activity and void of any significant D.sub.2 receptor binding properties are disclosed. Methods for their preparation also are described.

Benzoxepins as intermediates to 5HT.sub.3 antagonists

Quinolinyl ether or thioether tetrazoles as agents for the treatment of

Certain specific substituted 9-N-(1-azabicyclo[3.3.1.]nonan-4-yl)carboxamido-2,3,4,5-tetrahydro-1-benzo xepins and their valuable use as 5-HT.sub.3 antagonists having CNS and gastric prokinetic activity and void of any significant D.sub.2 receptor binding properties are disclosed. Methods for their preparation also are described.

Certain benzoxepins and their pharmaceutical compositions and methods

Certain specific substituted 9-N-(1-azabicyclo-[2.2.2.]octan-3-yl)carboxamido-2,3,4,5-tetrahydro-1-benz oxepins and their valuable use as 5-HT.sub.3 antagonists having CNS and gastric prokinetic acticity and void of any significant D.sub.2 receptor binding properties are disclosed. Methods for their preparation also are described.

Quinuclidyl benzoxepins as 5-HT.sub.3 antagonists

Aryl and Heteroaryl Ethers are used for their anti-inflammatory and anti-allergic properties.

Growing community of inventors

Princeton Junction, NJ, United States of America

Raymond Youssefyeh